Due Diligence That Drives Decisions

Written By Christoph Meinert

Why One Checklist Never Fits Every Biotech Company

Most due diligence checklists begin with documents.

Corporate records. Intellectual property. Clinical data. Regulatory correspondence. Financial models. Manufacturing information.

These materials matter. But collecting them does not necessarily make a company ready for a transaction.

The more important question is:

Which decision must the available evidence enable?

An early-stage biotech preparing for a strategic collaboration faces a different decision from a clinical-stage company raising a major financing round. A company preparing for a business development and licensing process faces another set of expectations entirely.

The underlying areas of diligence may overlap, but their importance, weighting and required level of evidence change considerably.

This is why we do not apply a fixed checklist to every company.

We use a consistent decision-driven methodology, then adapt its categories, scoring and priorities to the company’s stage, objectives and counterparties.

The purpose is not simply to identify gaps. It is to determine which gaps matter now, how they could affect the next transaction and where management should focus its limited time and resources.

Start with the decision—not the data room

Before defining categories or requesting documents, we clarify four questions:

  • What decision is the company preparing for?

  • Who will make that decision?

  • What evidence will that counterparty expect?

  • What could prevent them from moving forward?

This changes the assessment from a broad review into a focused decision-support tool.

The same weakness can have very different consequences depending on the situation.

An early-stage company may not yet require a fully developed commercial-scale financial model. It may, however, need absolute clarity on operational responsibilities, product specifications and the conditions required for a partner to participate.

A company preparing for a large financing must demonstrate more than scientific promise. Investors need to understand capital requirements, development risks, valuation logic and how the next financing will create meaningful value.

In a licensing process, the key question may not be whether the asset is interesting. It may be whether a specific buyer has a compelling strategic and economic reason to act.

The assessment must therefore be built around the decision that matters most.

Case 1: Preparing for a strategic clinical collaboration

In one mandate, an early-stage biotech was preparing for due diligence with a potential clinical collaboration partner.

A generic investor-readiness checklist would not have addressed the immediate challenge.

The central question was:

Can the prospective partner participate responsibly, operationally and institutionally in the proposed program?

The framework therefore focused on areas such as:

  • Scientific and clinical rationale

  • Regulatory and safety readiness

  • Operational feasibility

  • Manufacturing and supply considerations

  • Legal and intellectual-property clarity

  • Partner motivation

  • Internal decision pathways

  • Financial and organizational credibility

The assessment showed that scientific interest alone was not enough.

The more important issues concerned execution: whether the proposed program was defined consistently, whether responsibilities were clear and whether the partner could navigate its own approval process.

This changed the company’s priorities.

Instead of spending most of its preparation time refining the scientific narrative, management focused on the practical questions that could determine whether the collaboration moved forward:

  • What exactly was the partner being asked to support?

  • Which responsibilities would sit with each party?

  • What information was still inconsistent or incomplete?

  • Which internal stakeholders needed to be involved?

  • What approvals, contracts and evidence would be required?

The diligence process changed the purpose of the next meeting. It was no longer simply an exploratory scientific discussion. It became a structured conversation about the decisions, responsibilities and next steps required to make the collaboration executable.

Case 2: Preparing for a major financing round

A second mandate involved a clinical-stage biotech preparing for a substantial institutional financing.

Here, the decision was fundamentally different:

Can investors underwrite the company’s risks and see a credible path from new capital to value creation?

The framework expanded accordingly. It assessed areas including:

  • Scientific and technical risk

  • Clinical development

  • Regulatory strategy

  • Intellectual property

  • Market and competitive positioning

  • Manufacturing and CMC

  • Team and governance

  • Financial planning

  • Financing strategy

  • Exit and partnering optionality

Each area was evaluated against the standards relevant to an institutional investor.

The assessment did not simply ask whether a financial model existed. It examined whether the model connected capital requirements to development milestones, downside scenarios and future financing needs.

It did not merely confirm the presence of intellectual property. It considered whether the protection strategy was sufficiently clear and defensible to support the investment case.

It did not treat exit potential as a generic slide in a presentation. It tested whether likely strategic pathways, comparable transactions and potential counterparties had been considered realistically.

This led to a different set of management decisions.

Some of the company’s scientific and operational foundations were relatively advanced. The most important work was therefore not necessarily to generate more scientific content. It was to strengthen the investment case around that science.

Priorities shifted toward:

  • Quantifying development and financing risks

  • Building a scenario-based financial model

  • Connecting funding requirements to value-inflection milestones

  • Strengthening intellectual-property and freedom-to-operate arguments

  • Clarifying valuation logic

  • Defining realistic partnering and exit pathways

  • Assigning ownership for investor-readiness workstreams

The assessment also distinguished between current readiness and achievable readiness after targeted remediation.

This was important because management did not need to solve every possible issue before beginning investor discussions. It needed to identify the actions that could most materially improve confidence, reduce perceived risk and strengthen the financing proposition.

Due diligence became a resource-allocation exercise.

Case 3: Preparing for a BD&L process

The third mandate concerned a clinical-stage company preparing for a business development and licensing process following an important data milestone.

The relevant question was no longer primarily about financing readiness:

Can a potential strategic partner understand the opportunity, see a reason to prioritize it and execute a transaction?

The framework was therefore adapted around six transaction-oriented areas:

  • Strategic positioning

  • Competitive differentiation

  • Data credibility

  • Buyer fit

  • Transaction readiness

  • Scalability and economic viability

The weighting also changed.

Transaction readiness and economic viability became more important because they could directly influence whether a potential partner was able to justify and execute a deal.

The assessment examined more than whether the asset had generated interesting results. It tested whether the opportunity was sufficiently actionable for a buyer.

That required answers to questions such as:

  • Is there a clear primary transaction thesis?

  • Which buyers have the strongest strategic rationale?

  • How does the opportunity fit their portfolios and priorities?

  • Is the differentiation clear relative to alternatives?

  • Can the economics work at the scale a buyer would require?

  • Is the data room structured around the questions a transaction team will ask?

  • Is management prepared for different interpretations of the results?

This changed decision-making again.

The company could have continued refining a broad corporate story. Instead, it concentrated on the factors most likely to determine strategic interest:

  • A focused transaction thesis

  • Buyer-specific positioning

  • Clear economic and scalability assumptions

  • Readout scenarios and objection handling

  • A transaction-ready data room

  • A structured approach to outreach and engagement

The central issue was not whether the opportunity was scientifically interesting.

It was whether a potential partner could see why it mattered to them—and why they should act.

The common framework

Although the three assessments used different categories and weightings, the underlying methodology remained consistent.

1. Define the next decision

Readiness only has meaning in relation to a specific objective.

A company may be ready for an early collaboration but not ready for institutional financing. It may be scientifically credible but not yet transaction-ready for a licensing process.

The first step is therefore to define the decision, the counterparty and the expected timing.

2. Translate diligence into the counterparty’s questions

The framework is designed from the outside in.

A clinical partner may focus on feasibility, responsibilities and operational risk.

An investor may focus on risk-adjusted value creation, financing requirements and downside protection.

A potential licensee may focus on strategic fit, differentiation, economics and execution risk.

The categories must reflect how the decision-maker evaluates the opportunity—not simply how the company organizes its internal files.

3. Evaluate evidence, not presentation quality

A strong narrative is valuable, but it is not a substitute for evidence.

For each requirement, we distinguish between:

  • The claim being made

  • The available supporting evidence

  • The level of evidence expected at the current stage

  • The remaining gap

  • The consequence if that gap is not resolved

This helps separate genuine readiness from a polished presentation.

4. Adjust scoring to stage and purpose

The same evidence can receive a different score depending on the decision being prepared for.

An initial regulatory rationale may be sufficient for an early partner discussion but inadequate for a major financing or licensing process.

A preliminary commercial model may support strategic exploration but not a buyer’s internal valuation case.

Scoring must therefore be relative to the company’s current objective, rather than based on a universal definition of perfection.

5. Prioritize consequences, not just gaps

A low score does not automatically make an item urgent.

A gap becomes a priority when it could:

  • Stop a transaction

  • Delay a decision

  • Reduce valuation

  • Increase perceived risk

  • Damage credibility

  • Prevent a counterparty from progressing internally

This is where the framework becomes most useful.

Management teams are often aware of dozens of weaknesses. The challenge is deciding which ones deserve attention now.

By combining readiness, criticality and timing, the assessment identifies the limited number of topics that can materially change the next decision.

6. Turn findings into workstreams

The final output should not be a long list of disconnected recommendations.

It should translate the most important findings into a small number of clearly owned workstreams, each linked to a decision or transaction outcome.

Depending on the company, these may include:

  • Strengthening the financial and financing model

  • Clarifying operational responsibilities

  • Building a partner-specific value proposition

  • Resolving critical IP questions

  • Improving transaction documentation

  • Developing an evidence-based valuation case

  • Preparing for key objections and downside scenarios

This enables management to act rather than simply acknowledge the findings.

A framework that adapts without losing discipline

A flexible framework does not mean an unstructured process.

Across stages and transaction types, several themes appear consistently:

  • Scientific credibility

  • Clinical and regulatory feasibility

  • Operational execution

  • Intellectual-property defensibility

  • Financial and economic viability

  • Stakeholder alignment

  • Transaction readiness

What changes is their relative importance, the level of evidence required and the consequence of being unprepared.

That adaptability is essential in biotech, where companies operate with limited resources and must continuously decide which risks to address, which opportunities to pursue and which evidence to generate next.

A useful due diligence process should therefore do more than determine whether documents are complete.

It should help management answer:

What are the most important decisions in front of us, and what must be true for us to make them well?

That is when due diligence becomes more than a checklist.

It becomes a tool for strategic focus, capital allocation and transaction execution.

Christoph Meinert